Patents Examined by Jeffrey S. Parkin
  • Patent number: 11028133
    Abstract: The invention relates to isolated recombinant analogues of flavivirus E-protein fusion loops comprising at least one glycosylation site for an N-linked glycan that is not present in the natural flavivirus E-protein fusion loop sequence, wherein the at least one glycosylation site is an N-linked glycosylation sequon (Asn-X-Ser/Thr) and the Asn (N) residue of the sequon occupies any of positions 98-110 (SEQ ID NO: 1) (DRGWGNGCGLFGK) of the natural flavivirus E-protein fusion loop amino acid sequence, wherein X is any amino acid residue except proline and Ser/Thr denotes a serine or threonine residue.
    Type: Grant
    Filed: May 22, 2017
    Date of Patent: June 8, 2021
    Assignee: Excivion LTD
    Inventor: Peter Laing
  • Patent number: 11028152
    Abstract: Described herein are single-domain antibodies that might serve as alternatives to conventional monoclonal antibodies for either the detection or treatment of Chikungunya Virus (CHIKV).
    Type: Grant
    Filed: July 17, 2019
    Date of Patent: June 8, 2021
    Assignee: The Government of the United States of America, as represented by the Secretary of the Navy
    Inventors: Jinny Lin Liu, George P. Anderson, Ellen R. Goldman
  • Patent number: 11007260
    Abstract: Aspects of the disclosure relate to nucleic acid vaccines. The vaccines include one or more RNA polynucleotides having an open reading frame encoding one or more Chikungunya antigen(s), one or more Zika virus antigens, and one or more Dengue antigens. Methods for preparing and using such vaccines are also described.
    Type: Grant
    Filed: July 21, 2016
    Date of Patent: May 18, 2021
    Assignee: ModernaTX, Inc.
    Inventors: Giuseppe Ciaramella, Eric Yi-Chun Huang, Kapil Bahl, Tai Zaks, Sunny Himansu
  • Patent number: 10981976
    Abstract: The present invention features anti-HERV-K monoclonal antibodies or antigen-binding portions thereof. The present invention also features uses of the antibodies for treating HIV infection or HIV-associated conditions or diseases.
    Type: Grant
    Filed: August 30, 2017
    Date of Patent: April 20, 2021
    Assignees: University of Rochester, Oregon Health & Science University, George Washington University
    Inventors: James J. Kobie, Jonah B. Sacha, Douglas F. Nixon
  • Patent number: 10973907
    Abstract: Compositions and vaccine combinations containing synthetic HIV envelope proteins, and methods for inducing an immune response against human immunodeficiency virus (HIV) infection are described. Viral expression vectors encoding the synthetic HIV envelope proteins can be used in the vaccine combinations to induce immune responses against HIV and provide improved protective immunity against HIV.
    Type: Grant
    Filed: June 13, 2019
    Date of Patent: April 13, 2021
    Assignee: Janssen Vaccines & Prevention B.V.
    Inventors: Johannes Petrus Maria Langedijk, Danielle Van Manen, Jort Vellinga, Frank Wegmann, Benoit Christophe Stephan Callendret, Anders Krarup, Jörn Stitz
  • Patent number: 10968255
    Abstract: In certain aspects the invention provides HIV-1 immunogens, including HIV-1 envelope selections from individual CH505, and methods for swarm immunizations using combinations of HIV-1 envelopes.
    Type: Grant
    Filed: March 1, 2017
    Date of Patent: April 6, 2021
    Assignees: Duke University, Triad National Security, LLC
    Inventors: Barton F. Haynes, Mattia Bonsignori, Hua-Xin Liao, Bette T. Korber, Peter T. Hraber, Kevin Saunders
  • Patent number: 10968254
    Abstract: Human immunodeficiency virus (HIV) envelope proteins having specified mutations that stabilize the trimeric form of the envelope protein are provided. The HIV envelope proteins described herein have an improved percentage of trimer formation and/or an improved trimer yield. Also provided are particles displaying the HIV envelope proteins, nucleic acid molecules and vectors encoding the HIV envelope proteins, as well as compositions containing the HIV envelope proteins, particles, nucleic acid, or vectors.
    Type: Grant
    Filed: July 19, 2018
    Date of Patent: April 6, 2021
    Assignee: Janssen Vaccines & Prevention B.V.
    Inventors: Johannes Petrus Maria Langedijk, Lucy Rutten, Nika Mindy Strokappe, Daphné Truan
  • Patent number: 10960380
    Abstract: An adsorbent, which can be produced by a method in which a particle size, a pore size, a specific surface area or the like can be easily controlled, and is suitable for isolation of biomolecules. The adsorbent contains aggregates of calcium phosphate-based particles, and has an average pore size of 15 to 36 nanometers and a specific surface area of 40 to 90 m2/mL when measurement is carried out by mercury porosimetry.
    Type: Grant
    Filed: December 20, 2016
    Date of Patent: March 30, 2021
    Assignees: JNC CORPORATION, SofSera Corporation
    Inventors: Yoshihiro Matsumoto, Akihiro Uchida, Yasuto Umeda
  • Patent number: 10947277
    Abstract: Transcriptional units encoding Zika virus (ZIKV) premembrane (prM) and envelope (E) proteins, which upon translation form Zika virus-like particles (VLPs), are described. Use of the transcriptional units and VLPs in three different ZIKV vaccine platforms is described. Immunoassay-based detection methods using ZIKV VLPs are described for the diagnosis of ZIKV infection.
    Type: Grant
    Filed: June 9, 2017
    Date of Patent: March 16, 2021
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Gwong-Jen J. Chang, Brent S. Davis
  • Patent number: 10946090
    Abstract: The present invention relates, in general, to an immunogen and, in particular, to an immunogen for inducing antibodies that neutralizes a wide spectrum of HIV primary isolates and/or to an immunogen that induces a T cell immune response. The invention also relates to a method of inducing anti-HIV antibodies, and/or to a method of inducing a T cell immune response, using such an immunogen. The invention further relates to nucleic acid sequences encoding the present immunogens.
    Type: Grant
    Filed: November 15, 2017
    Date of Patent: March 16, 2021
    Assignees: Duke University, The University of Alabama at Birmingham Research Foundation, Triad National Security, LLC
    Inventors: Barton F. Haynes, Feng Gao, Bette T. Korber, Beatrice H. Hahn, George M. Shaw, Denise L. Monti, Ying Ying Li, Julie Decker, Hua-Xin Liao
  • Patent number: 10934345
    Abstract: Broadly neutralizing antibodies against HIV-1 which specifically bind to gp120 of HIV-1, a method of preparing such antibodies and the use thereof are provided.
    Type: Grant
    Filed: January 26, 2017
    Date of Patent: March 2, 2021
    Assignees: NATIONAL CENTER FOR AIDS/STD CONTROL AND PREVENTION, CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION, THE SCRIPPS RESEARCH INSTITUTE
    Inventors: Yiming Shao, Jiang Zhu, Yuxing Li, Ian A. Wilson, Leopold Kong, Bin Ju, Linling He, Li Ren, Yajing Chen, Jiandong Liu
  • Patent number: 10906941
    Abstract: The present invention relates, in general, to human immunodeficiency virus-1 (HIV-1) particular, to a polyvalent vaccine for HIV-1 and to methods of making and using same.
    Type: Grant
    Filed: April 15, 2014
    Date of Patent: February 2, 2021
    Inventors: Jerome Kim, Morgane Rolland, Bette T. Korber, Barton F. Haynes
  • Patent number: 10894820
    Abstract: The invention relates to an antibody, a fragment or a derivative thereof, for use as an antiretroviral drug targeting a virus belonging to human endogenous retroviruses type W (HERV-W), wherein said antibody, fragment or derivative thereof is directed against HERV-W Envelope protein (HERV-W Env). The invention also relates to a composition comprising said antibody and a retroviral reverse-transcriptase inhibitory drug, for use as an antiretroviral drug targeting a virus belonging to HERV-W.
    Type: Grant
    Filed: March 22, 2019
    Date of Patent: January 19, 2021
    Assignee: GENEURO SA
    Inventors: Herve Perron, Francois Curtin, Alois Lang, Raphael Faucard, Julie Medina, Alexandra Madeira, Nadege Gehin
  • Patent number: 10894078
    Abstract: Provided herein are HIV-1 vaccines comprising a carrier and a population episensus antigen determined using the EpiGraph approach. Also provided are HIV-1 vaccines comprising a carrier, a population episensus antigen, and a tailored antigen. Also provided are methods of designing and producing an HIV-1 vaccine for a subject comprising designing vaccine antigens to optimally cover the diversity within a geographic area using an antigen amino acid sequence generated using the EpiGraph approach, and producing said designed vaccine antigen. Also provided are methods of inducing an effector memory T cell response comprising designing the one or more EpiGraph amino acid sequences, producing a vaccine comprising the one or more EpiGraph amino acid sequences and a vector, and administering the vaccine to a subject. Further provided are methods of treating HIV-1 in a subject comprising administering an effective amount of the described HIV-1 vaccines to the subject in need thereof.
    Type: Grant
    Filed: October 5, 2015
    Date of Patent: January 19, 2021
    Assignees: Vir Biotechnology, Inc., Triad National Security, LLC, Oregon Health & Science University
    Inventors: Eric Bruening, Klaus Frueh, Louis Picker, Bette T. M. Korber, James Theiler, Emily Marshall
  • Patent number: 10882907
    Abstract: Multispecific antibodies (e.g., bispecific antibodies) that bind to HIV gp120 and CD3 are disclosed. Also disclosed are methods of using such antibodies to treat or prevent HIV infection.
    Type: Grant
    Filed: June 21, 2018
    Date of Patent: January 5, 2021
    Assignee: GILEAD SCIENCES, INC.
    Inventors: Doug Rehder, Matthew R. Schenauer, Heather Stephenson, Nathan D. Thomsen
  • Patent number: 10882903
    Abstract: Methods and pharmaceutical compositions for preventing, treating or suppressing symptoms of a disorder associated with an alphavirus infection. In particular, the present invention relates to preventing, treating or suppressing symptoms of a disorder associated with an alphavirus infection through inhibiting the activity and/or expression of Transforming Growth Factor Beta (TGF-?) in a subject suffering from or at risk for suffering from an alphavirus infection.
    Type: Grant
    Filed: May 18, 2016
    Date of Patent: January 5, 2021
    Assignee: ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA
    Inventors: Janko Nikolich-Zugich, Jennifer Uhrlaub
  • Patent number: 10870682
    Abstract: The present invention provides compositions and methods of use comprising a chimeric dengue virus E glycoprotein comprising a dengue virus E glycoprotein backbone, which comprises amino acid substitutions that introduce an epitope that is recognized by an antibody from a dengue virus serotype that is different from the dengue virus serotype of the dengue virus E glycoprotein backbone.
    Type: Grant
    Filed: August 20, 2018
    Date of Patent: December 22, 2020
    Assignee: The University of North Carolina at Chapel Hill
    Inventors: William Messer, Ralph Baric, Aravinda de Silva, Boyd Yount
  • Patent number: 10849975
    Abstract: The present invention provides methods and compositions for inducing an immune response that confers dual protection against infections by either or both of a rabies virus and a filovirus, and/or which can be used therapeutically for an existing infection with rabies virus and/or a filovirus to treat at least one symptom thereof and/or to neutralize or clear the infecting agents. In particular, the present invention provides a recombinant rabies virus vector comprising a nucleotide sequence encoding at least one filovirus glycoprotein or an immunogenic fragment thereof, as well as pharmaceutical compositions comprising the vaccine vectors.
    Type: Grant
    Filed: February 2, 2012
    Date of Patent: December 1, 2020
    Assignees: Thomas Jefferson University, The United States of America, as Represented by the Secretary, Department of Health and Human Services Services
    Inventors: Joseph E. Blaney, Jason Paragas, Peter Jahrling, Reed Johnson, Matthias Schnell
  • Patent number: 10849969
    Abstract: A recombinant attenuated Mopeia virus (MOPV) comprising a recombinant genomic S segment that encodes a nucleoprotein having attenuated exonuclease activity, and optionally further encodes a non-MOPV arenavirus glycoprotein. Use of the recombinant attenuated MOPV to induce an immune response in a subject.
    Type: Grant
    Filed: October 24, 2016
    Date of Patent: December 1, 2020
    Assignee: INSTITUT PASTEUR
    Inventors: Sylvain Baize, Audrey Page, Xavier Carnec, Mathieu Jean Simon Mateo, Stephanie Reynard, Alexandra Fizet
  • Patent number: 10844107
    Abstract: The instant invention provides TCRs having one or more amino acid substitutions that bind to the AL9 epitope of the HIV protein vpr (AIIRILQQQL).
    Type: Grant
    Filed: July 25, 2017
    Date of Patent: November 24, 2020
    Assignee: ALTOR BIOSCIENCE, LLC
    Inventors: Marilyn Fernandez, Bai Liu, Warren Marcus, Hing C. Wong